A prospective phase II trial of 10-fraction whole-breast radiotherapy following breast-conserving surgery.
OpenAlex 토픽 ·
Breast Cancer Treatment Studies
Breast Lesions and Carcinomas
Breast Implant and Reconstruction
[BACKGROUND] Moderate hypofractionation is established as the standard of care for adjuvant whole-breast radiotherapy after breast-conserving surgery.
APA
Yirong Xiang, Jian Tie, et al. (2026). A prospective phase II trial of 10-fraction whole-breast radiotherapy following breast-conserving surgery.. Clinical and translational radiation oncology, 59, 101149. https://doi.org/10.1016/j.ctro.2026.101149
MLA
Yirong Xiang, et al.. "A prospective phase II trial of 10-fraction whole-breast radiotherapy following breast-conserving surgery.." Clinical and translational radiation oncology, vol. 59, 2026, pp. 101149.
PMID
41953587
Abstract
[BACKGROUND] Moderate hypofractionation is established as the standard of care for adjuvant whole-breast radiotherapy after breast-conserving surgery. Ultra-hypofractionated regimens further shorten treatment but have raised concerns about toxicity and cosmetic outcomes. In younger Asian patients frequently requiring a boost, we evaluated a 10-fraction whole-breast radiotherapy schedule as a practical and tolerable choice.
[METHODS] This single-arm, prospective phase II trial enrolled 64 patients with early-stage breast cancer at Peking University Cancer Hospital between November 2023 and March 2025. All patients received intensity-modulated radiotherapy (IMRT) with a prescribed dose of 37 Gy in 10 fractions, followed by a sequential tumor-bed boost of 7.4 Gy in 2 fractions according to clinical indications. The primary endpoint was the incidence of grade ≥2 acute radiation dermatitis; secondary endpoints included patient-reported outcomes, cosmetic assessment, oncologic outcomes and exploratory immune profiling. Clinical Trial registration: ChiCTR2300075391.
[RESULTS] All patients completed radiotherapy without interruption. Tumor-bed boost was delivered to 58 patients (90.6%). Grade 2 acute dermatitis was observed in 17.2% of patients, with no grade ≥3 events, and all reactions resolved to grade 0-1 within three months. Among the 11 cases with grade 2 dermatitis, the most frequently affected site was the nipple-areola complex (6 cases, 54.5%). Patient-reported cosmetic and breast symptom scores transiently worsened at two weeks after radiotherapy but recovered thereafter. No significant decline occurred in functional or global quality-of-life domains. Exploratory analyses suggested that prior chemotherapy and lower baseline CD4 T-cell counts were associated with a higher risk of grade ≥2 dermatitis.
[CONCLUSION] This 10-fraction whole-breast radiotherapy regimen was acceptable. These findings support this regimen as a practical alternative for adjuvant breast radiotherapy.
[METHODS] This single-arm, prospective phase II trial enrolled 64 patients with early-stage breast cancer at Peking University Cancer Hospital between November 2023 and March 2025. All patients received intensity-modulated radiotherapy (IMRT) with a prescribed dose of 37 Gy in 10 fractions, followed by a sequential tumor-bed boost of 7.4 Gy in 2 fractions according to clinical indications. The primary endpoint was the incidence of grade ≥2 acute radiation dermatitis; secondary endpoints included patient-reported outcomes, cosmetic assessment, oncologic outcomes and exploratory immune profiling. Clinical Trial registration: ChiCTR2300075391.
[RESULTS] All patients completed radiotherapy without interruption. Tumor-bed boost was delivered to 58 patients (90.6%). Grade 2 acute dermatitis was observed in 17.2% of patients, with no grade ≥3 events, and all reactions resolved to grade 0-1 within three months. Among the 11 cases with grade 2 dermatitis, the most frequently affected site was the nipple-areola complex (6 cases, 54.5%). Patient-reported cosmetic and breast symptom scores transiently worsened at two weeks after radiotherapy but recovered thereafter. No significant decline occurred in functional or global quality-of-life domains. Exploratory analyses suggested that prior chemotherapy and lower baseline CD4 T-cell counts were associated with a higher risk of grade ≥2 dermatitis.
[CONCLUSION] This 10-fraction whole-breast radiotherapy regimen was acceptable. These findings support this regimen as a practical alternative for adjuvant breast radiotherapy.
같은 제1저자의 인용 많은 논문 (5)
- Co-delivery nanoparticle targeting CAF for simultaneous activating T cell plus NKT cell attack in solid tumor.
- In-depth Evaluation of the Olink Target 48 Cytokine Panel: Inter-Laboratory Evaluation of Performance and Reliability for Biomarker Studies in Oncology.
- Short-chain fatty acids in the tumor microenvironment: from molecular mechanisms to cancer therapy.
- Construction of circadian clock signature for tumor microenvironment in predicting survival of esophageal squamous cell carcinoma.
- Response to "Critical appraisal of a machine learning model for predicting internal mammary lymph node metastasis in breast cancer".